CSRP1 is a potential therapeutic targets for DLBCL: A computational analysis and in vitro experiments
Wanlu Tian, Fengbo Jin, Yingying Chen, Mingzhen Yang · 2025
Read CSRP1 is a potential therapeutic targets for DLBCL: A computational analysis and in vitro experiments by Wanlu Tian, Fengbo Jin, Yingying Chen, Mingzhen Yang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12705785.txt.
Description
Wanlu Tian and co-authors identify a cell protein, CSRP1, as a possible drug target in diffuse large B-cell lymphoma, in a study from 2025. The protein's role in this common, aggressive blood cancer had never been reported. The team mined several public datasets for expression, pathway, and immune patterns tied to it.
The protein was strongly overproduced in tumor samples compared with normal tissue. Its levels tracked with cell cycle pathways and with the immune makeup around the tumor. Lab experiments then confirmed the link: adjusting the protein changed how lymphoma cells died and moved through their division cycle. The authors offer the protein as a target candidate and a base for treatment research.
Catalog record
| CREATOR | Wanlu Tian, Fengbo Jin, Yingying Chen, Mingzhen Yang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |